<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03509870</url>
  </required_header>
  <id_info>
    <org_study_id>2015-005580-16</org_study_id>
    <nct_id>NCT03509870</nct_id>
  </id_info>
  <brief_title>Bone Marrow Derived Allogeneic Mesenchymal Stromal Cells to Non-healing Diabetic Foot Wounds</brief_title>
  <acronym>REDDSTAR</acronym>
  <official_title>Uncontrolled Non-randomised Single Dose Study of Topically Applied Bone Marrow Derived Allogeneic Mesenchymal Stromal Cells (REDDSTAR (ORBCEL-M)) in Patients With Non-healing Neuroischaemic Diabetic Foot Wounds'</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Steno Diabetes Center Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      examine safety of topical application of single dose allogeneic bone marrow derived&#xD;
      mesenchymal stromal cells to non-healing diabetic foot ulcers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1.1 Trial Phase&#xD;
&#xD;
      Phase 1b&#xD;
&#xD;
      1.2 Trial Aims and Objectives&#xD;
&#xD;
      To examine the safety of topical application of a single dose of allogeneic bone marrow&#xD;
      derived mesenchymal stromal cells (REDDSTAR ORBCEL-M) seeded in a collagen scaffold to&#xD;
      patients with non-healing neuroischaemic diabetic foot wounds.&#xD;
&#xD;
      1.3 Patient Population&#xD;
&#xD;
      Patients with non-healing neuroischaemic diabetic foot wounds despite standard care.&#xD;
&#xD;
      1.4 Trial Setting&#xD;
&#xD;
      Steno Diabetes Center Copenhagen, Denmark and Zelo Phase I Unit, Bispebjerg Hospital,&#xD;
      Copenhagen, Denmark.&#xD;
&#xD;
      1.5 Trial Intervention&#xD;
&#xD;
      Topical application of allogeneic bone marrow derived mesenchymal stromal cells seeded in a&#xD;
      collagen scaffold to patients with non-healing neuroischaemic diabetic foot wounds.&#xD;
&#xD;
      1.6 Concurrent Control&#xD;
&#xD;
      Open label, uncontrolled, non-randomised, single dose study.&#xD;
&#xD;
      1.7 Sample Size&#xD;
&#xD;
      9&#xD;
&#xD;
      1.8 Method of Participant Assignment&#xD;
&#xD;
      Administration of a single dose of allogeneic bone marrow-derived mesenchymal stromal cells&#xD;
      seeded in a collagen scaffold.&#xD;
&#xD;
      1.9 Examination Points&#xD;
&#xD;
      0, 1 week, 2 weeks, 3 weeks, 4 weeks up until 12 weeks or until complete wound closure. After&#xD;
      the week 12 visit, or ulcer closure, whichever occurs first, each patient will return to the&#xD;
      clinic 1 (± 2 days), 2 (± 2 days), 4 (± 3 days), 8 (±3 days), and 12 (±3days) weeks later for&#xD;
      follow-up visits to for adverse events, assess wound, wound closure and durability.&#xD;
&#xD;
      1.10 Primary Outcome&#xD;
&#xD;
      Serious adverse events that are attributable to intervention.&#xD;
&#xD;
      1.11 Secondary Outcomes&#xD;
&#xD;
      Time to complete wound closure (defined as from treatment day 1 to the first visit when&#xD;
      closure is documented). Absolute and percent changes in wound area from baseline, at weekly&#xD;
      intervals throughout. Durability of wound closure as measured at 4 week intervals for 12&#xD;
      weeks from date of wound closure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    study stopped because of lack of recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">April 1, 2020</completion_date>
  <primary_completion_date type="Actual">April 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>unblinded single arm intervention</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>serious adverse events attributable to intervention</measure>
    <time_frame>24 weeks</time_frame>
    <description>Death&#xD;
Septicaemia&#xD;
Amputation of the limb administered with therapy&#xD;
Worsening of the ulcer of the limb administered with therapy&#xD;
Allergic reaction or anaphylaxis&#xD;
Abnormal laboratory results&#xD;
Local or systemic reaction requiring hospital admission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>healing</measure>
    <time_frame>24 weeks</time_frame>
    <description>time to complete wound closure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>mesenchymal stromal cells</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>mesenchymal stromal cells in collagen scaffold</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mesenchymal stromal cells</intervention_name>
    <description>mesenchymal stromal cells in a collagen scaffold</description>
    <arm_group_label>mesenchymal stromal cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-80 years.&#xD;
&#xD;
          2. Type 1 or Type 2 diabetes mellitus (with any kind or combination of pharmacological&#xD;
             treatment for disease and/or complications to disease).&#xD;
&#xD;
          3. HbA1c ≤ 97 mmol/mol (≤ 11%).&#xD;
&#xD;
          4. Males or non-pregnant females.&#xD;
&#xD;
          5. Understand trial information document.&#xD;
&#xD;
          6. Provide written informed consent.&#xD;
&#xD;
          7. Duration of (diabetic foot) wound &gt; 4 but &lt; 52 weeks.&#xD;
&#xD;
          8. Reduction of &lt; 50% area over 4 weeks despite standard care (standard care;&#xD;
             off-loading, weekly debridement, dressings, orthotic).&#xD;
&#xD;
          9. Wound area with sharp debridement of ≥ 0.5 but ≤ 4.0 cm2.&#xD;
&#xD;
         10. Clinically non-infected wound.&#xD;
&#xD;
         11. Texas wound stage 1a, 1c or 2a.&#xD;
&#xD;
         12. Location of wound below malleolus.&#xD;
&#xD;
         13. Affected limb toe pressure ≥ 40 mmHg.&#xD;
&#xD;
         14. An ankle-brachial systolic pressure index between 0.7 and 1.3.&#xD;
&#xD;
         15. Diagnosis of peripheral neuropathy using American Diabetes Association guidelines&#xD;
             (monofilament/vibration sensation/biothesiometer).&#xD;
&#xD;
         16. Able to adhere to study visit protocol.&#xD;
&#xD;
         17. Adhere to offloading devices/orthotic.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Life expectancy of less than 12 months.&#xD;
&#xD;
          2. Patients with a definite diagnosis of any immunodeficiency disorder.&#xD;
&#xD;
          3. Viral hepatitis [patient must have negative hepatitis B surface-antigen (HBsAg) and&#xD;
             hepatitis C antibody (HepCAb) test results obtained within 2 weeks prior to the&#xD;
             Treatment Day (Day 1)].&#xD;
&#xD;
          4. Active, uncontrolled connective tissue disease.&#xD;
&#xD;
          5. Renal failure as defined by serum creatinine &gt; 220 µmol/L.&#xD;
&#xD;
          6. Liver function tests that are &gt; 2.0 times Upper Limit Normal.&#xD;
&#xD;
          7. Poor nutritional status as measured by serum albumin &lt; 30 g/L.&#xD;
&#xD;
          8. Active cancer or a history of cancer in the 5 years prior to signing the informed&#xD;
             consent form (history of basal cell carcinoma is allowed).&#xD;
&#xD;
          9. Active wound infection (i.e. recent onset of erythema, oedema, and increased&#xD;
             temperature of the foot with normal radiographs).&#xD;
&#xD;
         10. Diabetic Charcot neuroarthropathy or other structural deformity that would prevent&#xD;
             adequate off-loading of the study foot.&#xD;
&#xD;
         11. Treatment with any systemic corticosteroid immunosuppressive chemotherapeutic agent,&#xD;
             antiviral, or previous/current radiation therapy to lower extremity to be treated&#xD;
             within 30 days prior to signing the informed consent form.&#xD;
&#xD;
         12. Having received another investigational drug or biologic within 30 days prior to&#xD;
             signing the informed consent form or currently participating in an investigational&#xD;
             drug or biologic study.&#xD;
&#xD;
         13. A psychiatric condition or chronic alcohol or drug abuse problem, determined from the&#xD;
             patient's medical history, which in the Investigator's opinion may pose a threat to&#xD;
             patient compliance.&#xD;
&#xD;
         14. History of non-compliance with treatment or clinical visit attendance (i.e. this study&#xD;
             requires that patients will comply with the protocol and ulcer care regimen).&#xD;
&#xD;
         15. Any unstable medical condition judged by the Principal Investigator that would cause&#xD;
             the study to be detrimental to the patient.&#xD;
&#xD;
         16. Wounds caused primarily by untreated vascular insufficiency, or where patients are&#xD;
             primarily eligible for vascular intervention to promote wound healing.&#xD;
&#xD;
         17. Wounds with an aetiology not related to diabetes.&#xD;
&#xD;
         18. More than three wounds on the target lower extremity.&#xD;
&#xD;
         19. The wound to be studied not anatomically distinct from another wound(s) (separated by&#xD;
             &lt; 1 cm from another wound or would interfere with standard of care treatment of&#xD;
             another wound. Only one single wound per one study subject can be treated in this&#xD;
             study.&#xD;
&#xD;
         20. Wounds which decrease in area by &gt; 50% during the screening 4-week run-in period.&#xD;
&#xD;
         21. Ulcers with underlying osteomyelitis on the leg with the wound to be treated.&#xD;
&#xD;
         22. Patients presenting with the clinical characteristics of cellulitis at the wound site&#xD;
             (suppurative inflammation involving particularly the subcutaneous tissue, often mild&#xD;
             erythema, tenderness, malaise, chills and fever).&#xD;
&#xD;
         23. Revascularization surgery on the leg with the wound to be treated ≤8 weeks prior to&#xD;
             signing the informed consent form.&#xD;
&#xD;
         24. Surgery to lengthen Achilles tendon on the leg with the wound to be treated ≤8 weeks&#xD;
             prior to signing the informed consent form.&#xD;
&#xD;
         25. Necrosis, purulence, or sinus tracts that cannot be removed by debridement on foot to&#xD;
             be treated.&#xD;
&#xD;
         26. Received dermal substitute or living skin equivalent within 30 days prior to signing&#xD;
             the informed consent form.&#xD;
&#xD;
         27. Received prior (Regranex®/becaplermin) therapy within 30 days prior to signing the&#xD;
             informed consent form.&#xD;
&#xD;
         28. Has known history of clinical sensitivity reactions to products of bovine origin or to&#xD;
             the primary or secondary dressings used in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Rossing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabetes Center Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Steno Diabetes Center Copenhagen</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

